Lotus Pharmaceuticals, Inc.'s Laevo-Bambuterol Received SFDA Approval to Commence Clinical Trials
BEIJING, April 29 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC") today reported that its innovative asthma drug Laevo-Bambuterol has received approval from China's State Food & Drug Administration's (SFDA) to commence clinical trials (No.2010L01309 and 2010L01399).